Amphastar Pharmaceuticals, Inc. Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment
Amphastar Pharmaceuticals, Inc. (AMPH) had Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment of $321.22 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization
us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment · last filed 2026-08-06
- 2026-06-30: Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment $321.22M.
- 2026-03-31: Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment $313.37M.
- 2025-12-31: Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment $306.27M.
- 2025-09-30: Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment $298.29M.
| Period end | Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment as first filed |
|---|---|---|
| 2026-06-30 | $321.22M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $313.37M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $306.27M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $298.29M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $290.48M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $279.98M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $271.59M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $266.19M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $258.18M 10-Q · filed 2024-08-09 | |
| 2024-03-31 | $251.61M 10-Q · filed 2024-05-10 | |
| 2023-12-31 | $245.30M 10-K · filed 2025-03-03 | |
| 2023-09-30 | $237.75M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $232.35M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $226.58M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $220.03M 10-K · filed 2024-02-29 | |
| 2022-09-30 | $213.19M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $208.03M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $203.25M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $199.62M 10-K · filed 2023-03-01 | |
| 2021-09-30 | $194.55M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $195.16M 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $189.24M 10-Q · filed 2021-05-07 | |
| 2020-12-31 | $184.15M 10-K · filed 2022-03-11 | |
| 2020-09-30 | $178.83M 10-Q · filed 2020-11-06 | |
| 2020-06-30 | $173.45M 10-Q · filed 2020-08-07 | |
| 2020-03-31 | $168.62M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $164.41M 10-K · filed 2021-03-15 | |
| 2019-09-30 | $160.06M 10-Q · filed 2019-11-08 | |
| 2019-06-30 | $156.26M 10-Q · filed 2019-08-09 | |
| 2019-03-31 | $152.24M 10-Q · filed 2019-05-10 | |
| 2018-12-31 | $149.09M 10-K · filed 2020-03-16 | |
| 2018-09-30 | $148.01M 10-Q · filed 2018-11-09 | |
| 2018-06-30 | $139.71M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $136.60M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $138.12M 10-K · filed 2019-03-15 | $133.33M 10-K · filed 2018-03-14 |
| 2017-09-30 | $130.38M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $127.47M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $124.33M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $122.01M 10-K · filed 2018-03-14 | |
| 2016-09-30 | $119.45M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $116.71M 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $114.99M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $112.26M 10-K · filed 2017-03-15 | |
| 2015-09-30 | $109.74M 10-Q · filed 2015-11-13 | |
| 2015-06-30 | $107.73M 10-Q · filed 2015-08-13 | |
| 2015-03-31 | $105.20M 10-Q · filed 2015-05-14 | |
| 2014-12-31 | $102.55M 10-K · filed 2016-03-15 | |
| 2014-09-30 | $99.33M 10-Q · filed 2014-11-13 | |
| 2014-06-30 | $96.16M 10-Q · filed 2014-08-13 | |
| 2013-12-31 | $90.58M 10-K · filed 2015-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |